Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1689-1697

  García Feijoo, Julian ^a,b   Martinez De La Casa J M ^a   Castillo, A ^a   Mendez C ^a   Fernandez Vidal A ^a   Garcia Sanchez J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Ocular hypertension; Prostaglandin; Travoprost

Indexed keywords

BRINZOLAMIDE; CARTEOLOL; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; RANDOMIZED CONTROLLED TRIAL; TONOMETRY;

AGED; CIRCADIAN RHYTHM; CLOPROSTENOL; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC;

EID: 33749029941     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X120959     Document Type: Article

References (30)

1. Carroll SC, Gaskin BJ, Goldberg I, et al. Glaucoma prescribing trends in Australia and New Zealand. Clin Exper Ophthalmol 2006;34:213-8
2. Gabelt BT, Kaufman PL. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402
3. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707-16
4. 2α. Arch Ophthalmol 1987;105:1112-6
5. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res 1995;23:519-25
6. 2+ mobilization and MAP kinase activation. J Ocular Pharmacol Ther 2003;19:437-56
7. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-80
8. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retinal Eye Res 2000;19:271-95
9. 2α effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 1995;36:2461-5
10. Van Alphen GW, Wilhelm PB, Elsenfeld PW. The effect of prostaglandins on the isolated internal muscles of mammalian eye, including man. Doc Ophthalmol 1977;42:394-415
11. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone and other FP prostaglandin receptor agonist analogs. Invest Ophthalmol Vis Sci 2003;44:715-21
12. Toris CB, Camras CB, Zhan G, et al. Effect of travoprost on diurnal and nocturnal aqueous humor dynamics in patients with ocular hypertension and glaucoma. Poster presented at: the American Glaucoma Society, March, 2005, Snowbird, UT
13. DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84-91
14. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
15. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63
16. Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132:860-8
17. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
18. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
19. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
20. Tarkkanen A, Leikola J. Postural variations of the intraocular pressure as measured with the Mackay-Marg tonometer. Acta Ophthalmol 1967;45:569-75
21. Friberg TR, Sanborn G, Weinreb RN. Intraocular and episcleral venous pressure increase during inverted posture. Am J Ophthalmol 1987;103:523-6
22. Tsukahara S, Sasaki T. Postural change of IOP in normal persons and in patients with primary wide open-angle glaucoma and low tension glaucoma. Br J Ophthalmol 1984;68:389-92
23. Buchanan RA, Williams TD. Intraocular pressure, ocular pulse pressure, and body position. Am J Optom Physiol Opt 1985;62:59-62
24. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42
25. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960;64:494-501
26. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 2005;139:320-4
27. Hirooka K, Shiraga F. Relationship between postural change of the intraocular pressure and visual field loss in primary open-angle glaucoma. J Glaucoma 2003;12:379-82
28. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389-95
29. Konstas AGP, Mikropoulos D, Kaltsos K, et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446-50
30. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453-7